PharmaEngine Inc
PharmaEngine Biotech Co., Ltd. is a virtual pharmaceutical company founded in 2003, specializing in cancer drug development using a virtual pharmaceutical company business model. The company focuses on developing new cancer therapies, including the marketed product ONIVYDE®, a nanotechnology-based liposomal formulation of camptothecin for metastatic pancreatic cancer treatment, approved in multiple major markets globally. PharmaEngine advances drug candidates such as PEP07 (CHK1 inhibitor) in Phase 1 clinical trials and PEP08 (PRMT5 inhibitor) at IND ready stage, preparing for clinical trials. The company leverages international strategic alliances and AI/CADD computational methods to select and develop drug candidates, aiming to reduce development risks and accelerate commercialization by licensing late-stage products to global pharmaceutical companies. PharmaEngine maintains a strong advisory board of international cancer experts and collaborates closely with CDMOs and CROs to optimize development and risk management, positioning itself as a professional and innovative cancer drug development company with a sustainable growth strategy.
PharmaEngine Inc
PharmaEngine Biotech Co., Ltd. is a virtual pharmaceutical company founded in 2003, specializing in cancer drug development using a virtual pharmaceutical company business model. The company focuses on developing new cancer therapies, including the marketed product ONIVYDE®, a nanotechnology-based liposomal formulation of camptothecin for metastatic pancreatic cancer treatment, approved in multiple major markets globally. PharmaEngine advances drug candidates such as PEP07 (CHK1 inhibitor) in Phase 1 clinical trials and PEP08 (PRMT5 inhibitor) at IND ready stage, preparing for clinical trials. The company leverages international strategic alliances and AI/CADD computational methods to select and develop drug candidates, aiming to reduce development risks and accelerate commercialization by licensing late-stage products to global pharmaceutical companies. PharmaEngine maintains a strong advisory board of international cancer experts and collaborates closely with CDMOs and CROs to optimize development and risk management, positioning itself as a professional and innovative cancer drug development company with a sustainable growth strategy.